Total Funding
83
68
Total FundingSeries D raised
Growth Score
-5 pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
4821
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Past Role: SHL Telemedicine, General Manager of US- Kelly Huang: President, CEO and Board Director
About the Company
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a
single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.
